Victoza shows positive results in LEADER trial
The study was conducted over a five-year period and involved more than 9,000 adults who have type 2 diabetes with a high chance of major negative cardiovascular events.
When the LEADER trial compared Victoza to the placebo -- added to cardiovascular standard of care -- it met the primary goal of proving that it was not inferior, instead demonstrating superiority to the placebo while significantly reducing cardiovascular risk. The primary goal of the study was the composite result of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. The vast reduction of major negative cardiovascular events shown by Victoza resulted in the three major components of the goal.
Patients who have type 2 diabetes usually have a much higher risk of cardiovascular events. Through the LEADER trial, Victoza has proven that it can help these patients control their blood sugar levels, which, in turn, helps to reduce adverse cardiovascular events.
Novo Nordisk will present the results of the LEADER trial at the 76th Scientific Sessions of the American Diabetes Association in June.